Update in diabetes and cardiovascular disease: Synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease

Current Opinion in Lipidology

Volumn 21, Issue 1, 2010, Pages 8-14

  Park, Lee ^a   Wexler, Deborah ^b  

^a NEWTON WELLESLEY HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Glucose control

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE DURATION; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 77649096094     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328332dfaa     Document Type: Review

References (25)

1. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421-431.
2. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994; 154:2473-2479.
3. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991; 81:1158-1162.
4. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003; 46:760-765.
5. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115:1544-1550.
6. Dorman JS, Laporte RE, Kuller LH, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 1984; 33:271-276.
7. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation 2002; 106:2760-2763.
8. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl 8A):6S-11S.
9. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
10. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
11. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-139.
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.
14. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
15. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
16. Kelly TN, Bazzano LA, Fonseca VA, et al. Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 150:803-808.
17. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta analysis of randomised controlled trials. Lancet 2009; 373:1765-1772.
18. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003; 17:314-322.
19. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
20. Tharmanathan P, Calvert M, Hampton J, Freemantle N. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. BMC Med Res Methodol 2008; 8:12.
21. DeMets DL, PocockSJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet 1999; 354:1983-1988.
22. New Analyses Shed Further Light On VADT and ACCORD Trial In: ADA 69th Scientific Sessions. new Orleans: ADA; 2009. pp 1,6.
23. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119:351-357.
24. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
25. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.